Crispr Therapeutics Ag

Cytomx Therapeutics, Inc.

Jonathan Alexander Terrett

Demetrios Kalaitzidis

Jason Gary Sagert

Lawrence Klein

James William West

Olga Vasiljeva

Stephen James Moore

Daniel Robert Hostetter

Luc Roland Desnoyers

Margaret Thy Luu Nguyen

Shweta Singh

Annie Yang Weaver

Mary-Lee Dequéant

Zinkal Samir Padalia

Li Mei

Margaret T L Nguyen

Kimberly Ann Tipton

Ewelina Morawa

Tony Ho

Hanspeter Waldner

John Kulman

Mark Benton

Laura Serwer

Sandeep Soni

Yi-Shan Chen

Jui Dutta-Simmons

The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies. Such genetically engineered T cells may comprise (i) a mutated gene involved in cell self-renewal; (ii) a disrupted gene involved in apoptosis; (iii) a disrupted gene involved in regulation of T cell exhaustion; or (iv) a combination of any one of (i)-(iii).

Genetically engineered T cells having improved persistence in culture

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as LIV1malignancies.

T-cells expressing anti-LIV1 chimeric antigen receptor

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.

Methods and compositions for treating cancer

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7malignancies.

Anti-PTK7 immune cell cancer therapy

The present disclosure relates to methods, compositions and kits for treating conditions that are related with angiopoietin-like 3 (ANGPTL3) by gene editing.

Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

Masked chimeric antigen receptor (CAR) constructs comprising an extracellular antigen binding domain specific tyrosine-protein kinase-like 7 (PTK7), which is linked to a mask peptide that blocks binding of masked CAR from binding to PTK7. Also provided herein are genetically engineered T cells expressing a masked CAR specific to PTK7 and therapeutic uses thereof.

Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (PTK7) and immune cells expressing such

The invention relates generally to antibodies that bind CD166, activatable antibodies that specifically bind to CD166 and methods of making and using these anti-CD166 antibodies and anti-CD166 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

Materials and methods for engineering cells and uses thereof in immuno-oncology

A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.

Growing community of inventors

Cambridge, MA, United States of America

Jonathan Alexander Terrett